Tonix Pharmaceuticals Holding Corp (TNXP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $58.49M
Last updated: Nov 17, 2026 at 4:28 PM ET
Tonix Pharmaceuticals Holding Corp (TNXP) Statistics
Tonix Pharmaceuticals Holding (TNXP) has a market cap of $58.49M. Its share count is up 106.67% from a year earlier. It kept -420.45% of revenue as net income over the last 12 months.
Total Valuation
| Market Cap | $58.49M |
|---|---|
| Latest price (Nov 17, 2026) | $2.94 |
Key Dates
The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 9, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 1.3x and 0.3x.
| P/S Ratio | 1.3x |
|---|---|
| Forward P/S | 1.0x |
| P/B Ratio | 0.3x |
Price Statistics
The stock is down 81.51% over 52 weeks and trades 59.78% below its 50-day average.
| Beta (1Y) | 1.65 |
|---|---|
| 52-Week Change | -81.51% |
| 1-Month Change | -48.69% |
| 3-Month Change | -76.90% |
| 6-Month Change | -78.56% |
| 5-Year Change | -100.00% |
| 10-Year Change | -100.00% |
| Total Return (1Y) | -81.51% |
| Total Return (3Y CAGR) | -87.53% |
| Total Return (5Y CAGR) | -90.20% |
| Return vs SPY (1Y) | -93.53% |
| Max Drawdown (1Y) | -85.52% |
| Max Drawdown (3Y) | -99.86% |
| Sharpe Ratio (1Y) | -2.34 |
| Correlation with SPY (1Y) | 0.31 |
| 50-Day Average | $7.31 |
| 200-Day Average | $11.65 |
| 52-Week Range | $2.81 to $20.56 |
| RSI (14 Days) | 12.7 |
| Average Volume (20 Days) | 1.07M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 4.57x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 4.57x |
|---|---|
| Quick Ratio | 4.47x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -90.73% over the last 12 months, against a 5-year average of -69.94%.
| Return on Equity (ROE) | -90.73% |
|---|---|
| Return on Assets (ROA) | -74.66% |
| ROE (5Y Average) | -69.94% |
| ROA (5Y Average) | -57.45% |
| ROIC (5Y Average) | -65.57% |
| Asset Turnover | 0.17x |
| Inventory Turnover | 1.00x |
| Receivables Turnover | 3.26x |
| Cash Conversion Cycle | -2395 days |
Scores
TNXP has an Altman Z-Score of -6.60, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -6.60 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $43.05M over the last 12 months is up 317.96% from the 12 months before.
| Revenue | $43.05M |
|---|---|
| Revenue Growth (YoY) | +317.96% |
| Gross Profit | $38.45M |
| Operating Income | -$187.79M |
| Pretax Income | -$182.32M |
| Net Income | -$180.99M |
| Reported EPS (TTM) | -$12.24 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 82.29% of the $242.43M in total assets.
| Cash and Equivalents | $162.79M |
|---|---|
| Total Debt | $0 |
| Net Cash | $162.79M |
| Net Cash Per Share | $8.83 |
| Working Capital | $150.11M |
| Shareholder Equity | $199.49M |
| Book Value Per Share | $10.82 |
| Total Assets | $242.43M |
| Total Liabilities | $42.94M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $4.76M of capital spending, operating cash flow left -$170.04M of free cash flow.
| Operating Cash Flow | -$165.28M |
|---|---|
| Capital Expenditures | $4.76M |
| Free Cash Flow | -$170.04M |
| FCF Per Share | -$9.91 |
| Depreciation and Amortization | $2.31M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -436.25%.
| Gross Margin | 89.33% |
|---|---|
| Operating Margin | -436.25% |
| Pretax Margin | -423.55% |
| Net Margin | -420.45% |
| FCF Margin | -395.02% |
Dividends and Yields
TNXP does not pay a dividend. Its free cash flow yield is -313.64%.
| FCF Yield | -313.64% |
|---|---|
| Buyback Yield | -260.23% |
| Shareholder Yield | -260.23% |
Stock Splits
The last split was a 1-for-100 reverse split on Feb 5, 2025.
| Last Split Date | Feb 5, 2025 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:100 |
Peer Position
Against 6 similar companies, TNXP has the 4th highest P/S.
P/S RatioPeer median 5.2x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -68.62%
| P/S Ratio | 1.3x vs 5.2x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +317.96% vs -68.62% median |
Analyst Forecast
Consensus estimates put revenue growth at 193.37% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +193.37% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About TNXP
What is TNXP's market cap?
Tonix Pharmaceuticals Holding has a market cap of $58.49M.
How many shares of TNXP are outstanding?
Tonix Pharmaceuticals Holding has 18.44M shares outstanding. The count is up 106.67% from a year earlier.
Does TNXP pay a dividend?
No. Tonix Pharmaceuticals Holding does not pay a dividend.
How much debt does TNXP have?
Tonix Pharmaceuticals Holding has $0 of total debt and $162.79M of cash and equivalents, a net cash position of $162.79M.
TNXP pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors